In a setback for the makers of branded drugs, the Indian Supreme Court dismissed Novartis' petition for patent protection for its cancer treatment Glivec. The landmark ruling reshapes the landscape for intellectual property disputes in the country and is likely to affect many other drugmakers. The decision will be an obstacle to bringing new treatments to patients, an executive with Novartis India said.

Related Summaries